157 related articles for article (PubMed ID: 35274007)
1. Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class.
Kaufman HL; Shalhout SZ; Iodice G
Front Mol Biosci; 2022; 9():834841. PubMed ID: 35274007
[TBL] [Abstract][Full Text] [Related]
2. Talimogene laherparepvec: overview, combination therapy and current practices.
O'Donoghue C; Doepker MP; Zager JS
Melanoma Manag; 2016 Dec; 3(4):267-272. PubMed ID: 30190898
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the oncolytic activity of a replication-competent and a replication-deficient herpes simplex virus 1.
Lindner G; Walter A; Magnus CL; Rosenhammer K; Holoborodko B; Koch V; Hirsch S; Grossmann L; Li S; Knipe DM; DeLuca N; Schuler-Thurner B; Gross S; Schwertner B; Toelge M; Rohrhofer A; Stöckl S; Bauer RJ; Knoll G; Ehrenschwender M; Haferkamp S; Schmidt B; Schuster P
Immunology; 2024 Jun; 172(2):279-294. PubMed ID: 38444199
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis.
Wang C; Lu N; Yan L; Li Y
Virol J; 2023 Nov; 20(1):252. PubMed ID: 37919738
[TBL] [Abstract][Full Text] [Related]
5. Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2).
Sun J; Gastman BR; McCahon L; Buchbinder EI; Puzanov I; Nanni M; Lewis JM; Carvajal RD; Singh-Kandah S; Desai AM; Raskin L; Nielson CM; Ismail R; Zager JS
Melanoma Manag; 2020 Jun; 7(2):MMT41. PubMed ID: 32821373
[TBL] [Abstract][Full Text] [Related]
6. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.
Kaufman HL; Ruby CE; Hughes T; Slingluff CL
J Immunother Cancer; 2014; 2():11. PubMed ID: 24971166
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis.
Xie R; Bi X; Shang B; Zhou A; Shi H; Shou J
Virol J; 2021 Jul; 18(1):158. PubMed ID: 34332591
[TBL] [Abstract][Full Text] [Related]
8. Biosafety and biohazard considerations of HSV-1-based oncolytic viral immunotherapy.
Robilotti E; Zeitouni NC; Orloff M
Front Mol Biosci; 2023; 10():1178382. PubMed ID: 37795219
[TBL] [Abstract][Full Text] [Related]
9. HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials.
Koch MS; Lawler SE; Chiocca EA
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33255871
[TBL] [Abstract][Full Text] [Related]
10. Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus
Sotiriadis S; Beil J; Berchtold S; Smirnow I; Schenk A; Lauer UM
Viruses; 2024 May; 16(5):. PubMed ID: 38793657
[TBL] [Abstract][Full Text] [Related]
11. Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective.
Franke V; Stahlie EHA; van der Hiel B; van de Wiel BA; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
J Immunother; 2022 Jul-Aug 01; 45(6):263-266. PubMed ID: 35580326
[TBL] [Abstract][Full Text] [Related]
12. From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses.
Kabiljo J; Laengle J; Bergmann M
Cell Death Discov; 2020; 6():48. PubMed ID: 32542113
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on immunotherapy via oncolytic viruses.
Reale A; Vitiello A; Conciatori V; Parolin C; Calistri A; Palù G
Infect Agent Cancer; 2019; 14():5. PubMed ID: 30792754
[TBL] [Abstract][Full Text] [Related]
14. Past, Present and Future of Oncolytic Reovirus.
Müller L; Berkeley R; Barr T; Ilett E; Errington-Mais F
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33142841
[TBL] [Abstract][Full Text] [Related]
15. Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence?
Wongariyapak A; Roulstone V; Melcher AA; Pedersen M; Harrington KJ
Ann Transl Med; 2023 Aug; 11(10):369. PubMed ID: 37675296
[No Abstract] [Full Text] [Related]
16. Virotherapy: cancer gene therapy at last?
Bilsland AE; Spiliopoulou P; Evans TR
F1000Res; 2016; 5():. PubMed ID: 27635234
[TBL] [Abstract][Full Text] [Related]
17. Attenuated Replication-Competent Herpes Simplex Virus Expressing an ECM-Modifying Transgene Hyaluronan Synthase 2 of Naked Mole Rat in Oncolytic Gene Therapy.
Palomäki J; Kalke K; Orpana J; Lund L; Frejborg F; Paavilainen H; Järveläinen H; Hukkanen V
Microorganisms; 2023 Oct; 11(11):. PubMed ID: 38004669
[TBL] [Abstract][Full Text] [Related]
18. Designer Oncolytic Adenovirus: Coming of Age.
Baker AT; Aguirre-Hernández C; Halldén G; Parker AL
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29904022
[TBL] [Abstract][Full Text] [Related]
19. Combined Regional Approach of Talimogene laherparepvec and Radiotherapy in the Treatment of Advanced Melanoma.
Tam A; Ladbury C; Kassardjian A; Modi B; McGee H; Melstrom L; Margolin K; Xing Y; Amini A
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893072
[TBL] [Abstract][Full Text] [Related]
20. Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment.
Khushalani NI; Harrington KJ; Melcher A; Bommareddy PK; Zamarin D
Mol Ther Oncolytics; 2023 Dec; 31():100729. PubMed ID: 37841530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
